Immutep reports Phase 1 IMP761 data showing exposure-dependent T-cell immune response inhibition

Immutep announced Phase 1 data for IMP761 showing statistically significant, exposure-dependent T-cell immune response inhibition, well tolerated across 7 dose levels with no serious adverse events.

Detected & updated continuously · Source: Nebula